Building off of last year’s successful new format, AACE is pleased to announce the newest edition of the AACE Self-Assessment Program (ASAP)!

After over a year of producing virtual events during an uncertain time, we are planning for a potential return to in-person events that brings both excitement and new opportunities. As a valued member of our AACE Community, I would like to be transparent with you and share how we are planning a return to in-person conferences in 2022.

Read more about thyroid eye disease, including recent research and case studies from Endocrine Practice and AACE Clinical Case Reports.

There is currently no reason to believe that most people with thyroid disease are at increased risk to contract this novel coronavirus or to experience complications. Nevertheless, if thyroid medications are not taken as prescribed, uncontrolled thyroid disease may increase a person’s risk for viral infection and complications.

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.

To coincide with Thyroid Awareness Month, the American Association of Clinical Endocrinologists (AACE) launched the Up To Here campaign on Monday to raise awareness of thyroid diseases and to help Americans recognize symptoms, risk factors and the need to seek treatment. More than 10% of Americans will develop a thyroid disease during their lives, yet many of those affected remain unaware of their condition.

The Medullary Thyroid Carcinoma (MTC) Registry Consortium* is partnering with the American Thyroid Association® (ATA) to create a registry (list) of adult (18 years of age and older) cases of MTC diagnosed in the United States in order to characterize their medical histories and possible risk factors, including history of treatment with long-acting GLP-1 RAs from January 1, 2010 to present (the MTC Registry).

Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.

Significantly more euthyroid patients with thyroid disease suffer from anxiety compared with depression, regardless of whether they have Hashimoto thyroiditis autoimmunity, according to research results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

Hypothyroidism is a risk factor for increased length of hospital stay and mortality in patients with congestive heart failure (CHF), according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress.

Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease, according to phase 3 confirmatory trial data presented at the AACE 28^th Annual Scientific & Clinical Congress.

For indeterminate thyroid nodules following fine needle aspiration, evidence of thick post-microcystic reflection on ultrasound was found to be associated with malignant nodules, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress.

The ThyroSeq v3 Genomic Classifier was able to effectively classify thyroid nodules with samples collected through fine needle aspiration (FNA), according to research reported by Lindsey Tolino, MBA, of the University of Pittsburgh Medical Center in Pennsylvania, and colleagues, at the AACE 28^th Annual Scientific & Clinical Congress.

The investigational agent teprotumumab was effective for reducing proptosis associated with thyroid eye disease, according to late-breaking phase III data presented by Raymond Douglas, MD, PhD, of Cedars Sinai Medical Center in Los Angeles, and colleagues, at the AACE 28^th Annual Scientific & Clinical Congress.